Understanding Circulating Tumor DNA (ctDNA) in Cancer Detection and Management

By: David Grew MD MPH

“The ability to perform this test frequently allows for real-time monitoring of disease progression and treatment response.”

∗ ∗ ∗

As a practicing radiation oncologist, I've often found myself explaining complex medical concepts to patients in ways they can easily understand. One such concept is circulating tumor DNA (ctDNA), sometimes called a “liquid biopsy”.  Recently I was caring for a patient with metastatic colorectal cancer and the medical oncologist suggested we perform periodic circulating tumor DNA tests to see whether the cancer had responded to treatment, or was growing through it.  This led to a really enlightening conversation about ctDNA, a revolutionary tool in cancer detection and management. 

In this blog, I’ll provide an overview of ctDNA and its significant implications for cancer care.

What is ctDNA?

Circulating tumor DNA, or ctDNA, originates from cancer cells and is found in the bloodstream. When cancer cells die and break down, they release small fragments of DNA into the blood. These fragments carry genetic changes specific to the cancer, making ctDNA a valuable biomarker for cancer detection and monitoring.

Key Points about ctDNA:

Detection and Diagnosis:

• Tumor Identification: ctDNA can detect genetic changes specific to cancer cells, aiding in tumor detection and diagnosis.
• Reduced Need for Invasive Biopsies: ctDNA testing can sometimes replace traditional tumor biopsies, offering a less invasive alternative.

Treatment Personalization:

• Targeted Therapy: ctDNA can help identify specific drugs for patients who may not respond to standard treatments like chemotherapy.
• Treatment Effectiveness: Monitoring changes in ctDNA levels can indicate how well a treatment is working, with decreasing levels suggesting tumor shrinkage.

Early Detection and Monitoring:

• Minimal Residual Disease (MRD): ctDNA tests are highly sensitive and can detect MRD before it's visible on imaging scans. This allows for earlier intervention with additional treatments.
• Correlating with Tumor Progression: ctDNA levels generally correlate with tumor size and progression, increasing as the tumor grows and decreasing with successful treatment.

How is ctDNA Analysis Done?

ctDNA analysis is performed through a blood test, commonly referred to as a liquid biopsy. Unlike traditional tissue biopsies, which involve surgically removing a sample of tissue from the tumor, a liquid biopsy is much less invasive. This process involves drawing a small amount of blood from the patient, which is then analyzed in a laboratory to detect and quantify ctDNA.

The analysis involves several steps:

1. Blood Collection: A blood sample is taken from the patient.
2. Plasma Separation: The blood sample is processed to separate the plasma, which contains the ctDNA, from the rest of the blood components.
3. DNA Extraction: ctDNA is extracted from the plasma using specialized techniques.
4. Genetic Analysis: The extracted ctDNA is analyzed for specific genetic mutations, alterations, or biomarkers that are indicative of cancer. This is often done using advanced techniques like next-generation sequencing (NGS) or digital PCR.

The ability to perform this test frequently allows for real-time monitoring of disease progression and treatment response. This frequent monitoring can provide critical insights into how well a treatment is working, allowing for timely adjustments to therapy if necessary.

Applications in Different Cancers

ctDNA testing is currently the most advanced and widely used in the management of colorectal cancer. However, its applications are expanding to other types of cancer as well. Some notable examples include:

1. Breast Cancer: ctDNA can be used to detect specific mutations associated with breast cancer, monitor treatment response, and detect minimal residual disease (MRD) or recurrence.
2. Non-Small Cell Lung Cancer (NSCLC): In 2016, the FDA approved the first ctDNA liquid biopsy test for detecting EGFR mutations in NSCLC patients. This allows for the identification of patients who may benefit from targeted therapies.
3. Muscle-Invasive Bladder Cancer: ctDNA is used to monitor treatment response and detect early signs of recurrence.

In each of these cancers, ctDNA provides a non-invasive method for detecting genetic mutations and alterations that can guide treatment decisions. It also allows for continuous monitoring of the disease, which can be crucial for adjusting treatments in response to changes in the tumor's genetic makeup.

Current Limitations and Future Prospects

While ctDNA testing offers many benefits, there are still some limitations to its widespread adoption:

1. Limited Detection in Early-Stage Cancers: ctDNA levels can be very low in early-stage cancers, making it difficult to detect and analyze. This limits its use primarily to advanced-stage cancers or for monitoring known metastatic disease.
2. Not Standardized Across All Cancer Types: While ctDNA testing is well-established for certain cancers, it is not yet standardized for all cancer types. More research and clinical validation are needed to expand its use.
3. Interpretation of Results: The presence of ctDNA indicates a high risk of recurrence or progression, but it does not necessarily mean immediate treatment is required. Interpreting these results in the context of clinical decision-making can be complex.

Future Prospects:

• Broader Applications: Ongoing research aims to expand ctDNA testing to more cancer types and to improve its sensitivity and specificity for early detection.
• Integration with Other Biomarkers: Combining ctDNA analysis with other biomarkers and imaging techniques could provide a more comprehensive picture of the cancer, leading to better-informed treatment decisions.
• Personalized Cancer Care: As our understanding of cancer genomics improves, ctDNA analysis is expected to play a key role in personalized cancer care, allowing for treatments tailored to the unique genetic profile of each patient's tumor.

∗ ∗ ∗

Circulating tumor DNA is transforming how we detect, diagnose, and manage cancer. It offers a less invasive method for monitoring disease progression and tailoring treatments to individual patients' needs and is crucial for both patients and healthcare providers as we move towards more personalized and effective cancer treatment strategies.

For more detailed information on ctDNA and its applications in cancer care, watch the video we created here.

Hire PRIMR to create custom video content for your clinical trial or medical product today.

‍

FAQs:

How accurate is ctDNA analysis compared to traditional tissue biopsies in detecting cancer?

While ctDNA analysis can detect genetic changes specific to cancer cells and offer a less invasive alternative to traditional biopsies, it may not always be as comprehensive as tissue biopsies. Traditional biopsies provide a more detailed analysis of the tumor microenvironment and architecture, which can be crucial for accurate diagnosis and treatment planning. However, ctDNA analysis is continually improving in sensitivity and specificity, making it a valuable tool for ongoing monitoring and certain diagnostic situations.

How often should ctDNA tests be performed to effectively monitor cancer progression or treatment response?

The frequency of ctDNA testing can vary depending on the type and stage of cancer, the treatment being administered, and the individual patient's condition. Generally, ctDNA tests are performed at baseline before starting treatment, periodically during treatment to monitor response, and after treatment to detect minimal residual disease or early signs of recurrence. The specific testing schedule should be determined by the healthcare provider based on the patient's unique circumstances.

What advancements are being made to expand the use of ctDNA testing to other cancer types?

Research is ongoing to improve the sensitivity and specificity of ctDNA testing for a wider range of cancer types. Advances in next-generation sequencing technologies and bioinformatics are enhancing the ability to detect and analyze ctDNA with greater accuracy. Clinical trials are also being conducted to validate ctDNA as a reliable biomarker for various cancers, including those where its use is currently limited. As these advancements continue, ctDNA testing is expected to become a more integral part of personalized cancer care across different types of cancer.